Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Content
    • Current Issue
    • Complete Issue PDF
    • Archive
    • Collections
    • Blog
  • Multimedia
    • Audio
    • Pediatrics On Call Podcast
  • CME/MOC
    • CME Quizzes
    • MOC Claiming
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Content
    • Current Issue
    • Complete Issue PDF
    • Archive
    • Collections
    • Blog
  • Multimedia
    • Audio
    • Pediatrics On Call Podcast
  • CME/MOC
    • CME Quizzes
    • MOC Claiming
  • Subscribe
  • Alerts
  • Careers
American Academy of Pediatrics
Neurology

Comparison of Initial Disease-Modifying Therapies in Pediatric MS

AAP Grand Rounds July 2020, 44 (1) 10; DOI: https://doi.org/10.1542/gr.44-1-10
  • Article
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Source: Krysko KM, Graves JS, Rensel M, et al. Real-world effectiveness of initial disease-modifying therapies in pediatric MS. Ann Neurol. 2020 8 April [published online ahead of print]; doi: 10.1002/ana.25737OpenUrlCrossRef

Investigators from multiple institutions conducted a retrospective study to compare the effectiveness of newer disease-modifying therapies (DMTs) to that of injectable DMTs in treating pediatric patients with multiple sclerosis (MS) or clinically isolated syndrome (CIS). Study participants were patients with onset of MS or CIS prior to the age of 18 years treated at 1 of 12 centers that are part of the US Network of Pediatric Multiple Sclerosis Centers and who were identified from network databases. Diagnoses were made using standardized criteria. Clinical data were collected on study participants using standardized case report forms. Patients were classified as receiving an injectable DMT (interferon-β, glatiramer acetate) or newer DMT, including dimethyl fumarate, fingolimod, teriflunomide, natalizumab, rituximab, ocrelizumab, and alemtuzumab. The primary outcome was relapse after starting DMT, …

View Full Text

Individual Login

Log in
You will be redirected to aap.org to login or to create your account.

Institutional Login

via Institution

You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Offer Reprints

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

AAP Grand Rounds
Vol. 44, Issue 1
1 Jul 2020
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of Initial Disease-Modifying Therapies in Pediatric MS
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Comparison of Initial Disease-Modifying Therapies in Pediatric MS
AAP Grand Rounds Jul 2020, 44 (1) 10; DOI: 10.1542/gr.44-1-10

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Quiz
Share
Comparison of Initial Disease-Modifying Therapies in Pediatric MS
AAP Grand Rounds Jul 2020, 44 (1) 10; DOI: 10.1542/gr.44-1-10
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents
  • Current Issue
  • Past Issues
  • Collections
  • Editorial Board
  • Overview
  • CME Quizzes
  • MOC Claiming

Jump to section

  • Article
    • Bottom Line
    • References
  • Info & Metrics
  • Comments

Related Articles

  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Medication Type Matters in Neonatal Seizures
  • No Neurodevelopmental Delay in Preemies With Grade I–II IVH
Show more NEUROLOGY

Similar Articles

  • Journal Info
  • Editorial Board
  • Overview
  • Licensing Information
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • shopAAP
  • AAP.org
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics